RTP Mobile Logo
Lung Cancer Update, Issue 3, 2011
Released January 2012

Featuring interviews with Drs Ronald B Natale, David R Spigel, Rafael Rosell and Martin Reck. (Text and Audio Content)

CE Disclosures and Faculty Information

  • OVERVIEW OF ACTIVITY

    Lung cancer is the leading cause of cancer mortality in the United States for both men and women, resulting in more deaths than breast, prostate, colon and pancreatic cancer combined. Progress in the screening, prevention and treatment of this disease has been limited, and approximately 85% of patients who develop lung cancer will die of it. Traditional chemotherapy, surgery and radiation therapy have had a modest effect on long-term outcomes. However, the advent of biologic agents in lung cancer has led to recent improvements in disease-free and overall survival in select patient populations. Published results from ongoing and completed studies lead to the continual emergence of novel therapeutic strategies and changes in the indications for existing treatments. In order to offer optimal patient care — including the option of clinical trial participation — the practicing clinician must be well informed of these advances. Featuring information on the latest research developments along with expert perspectives, this CME program is designed to assist medical oncologists and radiation oncologists with the formulation of up-to-date clinical management strategies for the care of patients with lung cancer.

    LEARNING OBJECTIVES

    • Use case-based learning to formulate individualized strategies for the care of patients with lung cancer.
    • Apply the results of emerging clinical research to the current and future treatment of non-small cell lung cancer (NSCLC).
    • Identify distinct subtypes of adenocarcinoma of the lung, including those with EGFR mutations and EML4-ALK gene fusions, and the investigational and approved treatment options for patients with these biomarkers.
    • Describe emerging efficacy and safety data on irreversible EGFR tyrosine kinase inhibitors, and identify patients who might benefit from participation in clinical trials evaluating these novel agents.
    • Identify patients with metastatic NSCLC who may experience incremental benefit from maintenance biologic therapy and/or chemotherapy.
    • Formulate an evidence-based treatment approach to adjuvant chemotherapy for NSCLC that recognizes the toxicities of different doublet regimens.
    • Use biomarkers, clinical characteristics and tumor histology to select individualized front-line treatment approaches for patients with NSCLC.
    • Recall the scientific rationale for ongoing investigation of novel agents or therapeutic approaches in lung cancer, and counsel appropriately selected patients about study participation.

    ACCREDITATION STATEMENT

    Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

    CME credit is no longer available for this issue

    CREDIT DESIGNATION STATEMENT

    CME credit is no longer available for this issue

    HOW TO USE THIS CME ACTIVITY

    This CME activity contains both audio and print components. The CME information, listen to the audio MP3s, and read the text portion.

    CME credit is no longer available for this issue

    CONTENT VALIDATION AND DISCLOSURES

    Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education. We assess potential conflicts of interest with faculty, planners and managers of CME activities. Real or apparent conflicts of interest are identified and resolved through a conflict of interest resolution process. In addition, all activity content is reviewed by both a member of the RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

    FACULTYDr Spigel had no real or apparent conflicts of interest to disclose. The following faculty (and their spouses/partners) reported real or apparent conflicts of interest, which have been resolved through a conflict of interest resolution process: Dr NataleAdvisory Committee: Amgen Inc, Boehringer Ingelheim Pharmaceuticals Inc, Pfizer Inc; Consulting Agreements: Genentech BioOncology, Lilly USA LLC; Paid Research: Lilly USA LLC, Novartis Pharmaceuticals Corporation. Dr RosellStock Ownership: Pangaea Biotech. Dr ReckAdvisory Committee: AstraZeneca Pharmaceuticals LP, Bristol-Myers Squibb Company, Daiichi Sankyo Inc, Lilly USA LLC, Pfizer Inc, Roche Laboratories Inc; Speakers Bureau: AstraZeneca Pharmaceuticals LP, Lilly USA LLC, Roche Laboratories Inc.

    EDITORDr Love is president and CEO of Research To Practice, which receives funds in the form of educational grants to develop CME activities from the following commercial interests: Abbott Laboratories, Allos Therapeutics, Amgen Inc, Astellas Pharma Global Development Inc, Bayer HealthCare Pharmaceuticals/Onyx Pharmaceuticals Inc, Biodesix Inc, Biogen Idec, Boehringer Ingelheim Pharmaceuticals Inc, Bristol-Myers Squibb Company, Celgene Corporation, Cephalon Inc, Daiichi Sankyo Inc, Dendreon Corporation, Eisai Inc, EMD Serono Inc, Genentech BioOncology, Genomic Health Inc, ImClone Systems, a wholly owned subsidiary of Eli Lilly and Company, Lilly USA LLC, Medivation Inc, Millennium: The Takeda Oncology Company, Mundipharma International Limited, Novartis Pharmaceuticals Corporation, Regeneron Pharmaceuticals, Sanofi, Seattle Genetics and Teva Pharmaceuticals.

    RESEARCH TO PRACTICE STAFF AND EXTERNAL REVIEWERS — The scientific staff and reviewers for Research To Practice have no real or apparent conflicts of interest to disclose.

    This educational activity contains discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantors.

    This activity is supported by educational grants from Boehringer Ingelheim Pharmaceuticals Inc, Celgene Corporation, Daiichi Sankyo Inc, EMD Serono Inc, Genentech BioOncology & OSI Oncology and Lilly USA LLC.

    Hardware/Software Requirements:
    An Internet connection that is at least 28.8 Kbps
    A monitor set to 1280 x 1024 pixels or more
    Internet Explorer 6.x or newer, Firefox 2.x or newer, or Safari 2.x or newer
    Macromedia Flash plug-in 6.0 or greater
    Adobe Acrobat Reader
    (Optional) Sound card and speakers for audio

    Last review date: January 2012
    Expiration date: January 2013

Acknowledge and close

Listen to audio:
Lung Cancer Update, Issue 3, 2011
Released January 2012

Featuring interviews with Drs Ronald B Natale, David R Spigel, Rafael Rosell and Martin Reck. (Text and Audio Content)

Read print: